Hengli Tang Phones & Addresses
-
9144 Shoal Creek Dr, Tallahassee, FL 32312 (850) 656-8287
-
3909 Reserve Dr, Tallahassee, FL 32311 (850) 656-8287
-
Freeport, FL
-
1105 Scrub Jay Ct, Carlsbad, CA 92009 (760) 804-9266
-
Los Angeles, CA
-
San Diego, CA
Business Records
Name / Title
Company / Classification
Phones & Addresses
Director
Biofront Technologies Inc
Nonclassifiable Establishments
Nonclassifiable Establishments
501 Blairstone Rd, Tallahassee, FL 32301
3000 Commonwealth Blvd, Tallahassee, FL 32303
3000 Commwl Blvd, Tallahassee, FL 32303
3000 Commonwealth Blvd, Tallahassee, FL 32303
3000 Commwl Blvd, Tallahassee, FL 32303
President
BIOFRONT INC
1105 Scrub Jay Ct, Carlsbad, CA 92009
Managing
Blue Prime Technologies, LLC
Business Services at Non-Commercial Site · Nonclassifiable Establishments
Business Services at Non-Commercial Site · Nonclassifiable Establishments
9144 Shl Crk Dr, Tallahassee, FL 32312
Publications
Amazon
Hepatitis C: Methods and Protocols (Methods in Molecular Biology)
When I was ?rst approached by Dr. Hengli Tang about writing the foreword to this book, the second edition of Hepatitis C Virus, I was a little puzzled: Book forewords are penned by persons far more famous than I am. Surely there were better people to write this, with a handful of the true visionarie...
Binding
Paperback
Pages
466
Publisher
Humana Press
ISBN #
1617378593
EAN Code
9781617378591
ISBN #
1
Us Patents
US Patent:
7910722, Mar 22, 2011
Filed:
Jul 3, 2008
Appl. No.:
12/167402
Inventors:
Hengli Tang - Tallahassee FL, US
Assignee:
Florida State University Research Foundation - Tallahassee FL
International Classification:
C07H 21/04
C07H 21/02
A61K 48/00
C12N 15/63
C07H 21/02
A61K 48/00
C12N 15/63
US Classification:
536 245, 514 44, 4353201, 536 231
Abstract:
Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc. , HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.
US Patent:
8252763, Aug 28, 2012
Filed:
Feb 28, 2011
Appl. No.:
13/036044
Inventors:
Hengli Tang - Tallahassee FL, US
Assignee:
Florida State University Research Foundation - Tallahassee FL
International Classification:
A61K 48/00
C07H 21/02
C07H 21/04
C12N 15/63
C07H 21/02
C07H 21/04
C12N 15/63
US Classification:
514 44, 536 231, 536 245, 4353201
Abstract:
Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C(HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc. , HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.
US Patent:
8318925, Nov 27, 2012
Filed:
Feb 25, 2011
Appl. No.:
13/034851
Inventors:
Hengli Tang - Tallahassee FL, US
Assignee:
Florida State University Research Foundation - Tallahaaee FL
International Classification:
C07H 21/04
C07H 21/02
A61K 48/00
C12N 15/63
C07H 21/02
A61K 48/00
C12N 15/63
US Classification:
536 245, 536 231, 536 2431, 536 2433, 514 44, 4353201
Abstract:
Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc. , HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.
US Patent:
8466274, Jun 18, 2013
Filed:
Oct 2, 2012
Appl. No.:
13/633199
Inventors:
Hengli Tang - Tallahassee FL, US
Assignee:
Florida State University Research Foundation - Tallahassee FL
International Classification:
C07H 21/04
C07H 21/02
A61K 48/00
C12N 15/63
C07H 21/02
A61K 48/00
C12N 15/63
US Classification:
536 245, 536 231, 536 2431, 536 2433, 514 44, 4353201
Abstract:
Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that target human cyclophilin A (CyPA) to inhibit Hepatitis C (HCV) infection. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc. , HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.
US Patent:
8563529, Oct 22, 2013
Filed:
Jul 26, 2012
Appl. No.:
13/558428
Inventors:
Hengli Tang - Tallahassee FL, US
Assignee:
Florida State University Research Foundation - Tallahassee FL
International Classification:
A61K 48/00
C07H 21/02
C07H 21/04
C12N 15/63
C07H 21/02
C07H 21/04
C12N 15/63
US Classification:
514 44, 536 231, 536 245, 4353201
Abstract:
Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that target human cyclophilin A (CyPA) to inhibit Hepatitis C (HCV) infection. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc. , HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.
US Patent:
20030039955, Feb 27, 2003
Filed:
May 10, 2001
Appl. No.:
09/853745
Inventors:
Yu Feng - San Diego CA, US
Hengli Tang - Carlsbad CA, US
Hengli Tang - Carlsbad CA, US
International Classification:
C12N007/00
C07H021/04
C12N015/86
C12N015/867
C12N015/863
C12Q001/70
C12N007/01
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
C07H021/04
C12N015/86
C12N015/867
C12N015/863
C12Q001/70
C12N007/01
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
US Classification:
435/005000, 435/235100, 435/320100, 435/456000, 536/023720
Abstract:
The invention provides methods to produce RNA viral sequences, recombinant RNA viruses, mutants of RNA viruses and RNA virus-derived vectors in cell culture and in vitro using non-viable, replication defective, helper vaccinia recombinants. These methods allow generation of RNA virus sequences and viral particles in cell culture and in vitro independent of their natural replication pathways, bypassing the limitation of any cellular barriers. The invention also provides novel RNA viral sequences and viral particles using these methods.
US Patent:
20130028965, Jan 31, 2013
Filed:
Oct 2, 2012
Appl. No.:
13/633276
Inventors:
HENGLI TANG - Tallahassee FL, US
Assignee:
Florida State University Research Foundation - Tallahassee FL
International Classification:
A61K 31/713
A61P 31/12
A61K 9/127
C07H 21/04
C12N 15/63
A61P 31/12
A61K 9/127
C07H 21/04
C12N 15/63
US Classification:
424450, 536 245, 4353201, 514 44 A
Abstract:
Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.
US Patent:
7759087, Jul 20, 2010
Filed:
Sep 28, 2006
Appl. No.:
11/536324
Inventors:
Hengli Tang - Tallahassee FL, US
Assignee:
The Florida State University Research Foundation, Inc. - Tallahassee FL
International Classification:
A01N 1/02
C12P 21/00
C12P 21/00
US Classification:
435 41, 435 4051, 435 42, 435325, 435 2
Abstract:
The invention discloses a method of maintaining hepatitis C virus (HCV) growing indefinitely in cell culture. The method includes providing a culture of cells susceptible to infection by HCV; introducing to the cell culture an inoculum containing an infective dose of HCV; contacting the inoculated cell culture with a growth medium containing an excess of uridine and cytidine; and changing spent growth medium with fresh growth medium containing the excess of uridine and cytidine on a predetermined schedule.